New treatments for eye diseases that cause vision loss
Novel Long-Acting Inhibitors of Vascular Endothelial Growth Factor (VEGF) for Treatment of Intraocular Vascular Disorders
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN DIEGO · NIH-10819539
This study is looking at new treatments for eye conditions that can cause serious vision loss, like age-related macular degeneration, by creating longer-lasting medications that might reduce the number of injections needed.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN DIEGO (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10819539 on ClinicalTrials.gov |
What this research studies
This research focuses on developing long-acting inhibitors of vascular endothelial growth factor (VEGF) to treat intraocular vascular disorders, particularly those leading to severe vision loss, such as age-related macular degeneration. The approach involves creating variants of VEGF receptor 1 that can bind effectively to the vitreous humor in the eye, potentially allowing for longer-lasting effects and reducing the need for frequent injections. By testing these new inhibitors in animal models, the researchers aim to demonstrate improved efficacy compared to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from neovascular age-related macular degeneration or other ischemic retinal diseases.
Not a fit: Patients with non-vascular eye disorders or those who do not have access to the required clinical settings may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with eye diseases, improving their vision and reducing the frequency of injections needed.
How similar studies have performed: Previous research has shown success with anti-VEGF therapies, indicating that novel approaches in this area have the potential for significant advancements.
Where this research is happening
LA JOLLA, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FERRARA, NAPOLEONE — UNIVERSITY OF CALIFORNIA, SAN DIEGO
- Study coordinator: FERRARA, NAPOLEONE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.